Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Suwon, South Korea

2 abstracts

Abstract
A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation.
Org: Yonsei Cancer Center and Severance Hospital, Suwon, South Korea,
Abstract
A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Org: Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Ulsan University Hospital, Ulsan, South Korea,